European Oncology Clinical Trials Have Declined
A new report highlights a significant drop in Europe's share of global cancer research initiatives since 2008.
Updated on Oct. 8, 2026 in Cancer
Live Poll
Should the European Union dedicate more of its competitiveness funding to cancer research?
The European Cancer Organisation has released a report detailing a steep decline in oncology clinical trials across Europe. The region's share of global trials fell from over 40% in 2008 to 21% by 2023.
Why it matters
Clinical trials often serve as a vital first line of treatment for patients facing advanced or rare cancer cases. This decline in research activity raises concerns about patient access to innovative therapies as cancer is projected to become Europe's leading cause of death by 2035.
Europe’s contribution to global oncology clinical trials dropped from over 40% in 2008 to 21% in 2023. During this same period, the number of oncology trials initiated by European companies saw an 8% decline.
The players
European Cancer Organisation
This is a non-profit federation that represents cancer professionals and patient advocacy groups across Europe.
The details
The report identifies complex, overlapping regulatory requirements such as the General Data Protection Regulation and medical device rules as primary barriers. Differing national interpretations of these mandates have created significant hurdles for the implementation of clinical trials across the European Union.
Timeline
In 2008, Europe accounted for over 40% of global clinical trials.
Between 2008 and 2023, European company-led oncology trials fell by 8%.
By 2023, Europe's share of global oncology trials had declined to 21%.
The European Cancer Organisation published its findings in October 2026.
Cancer is projected to become Europe's leading cause of death by 2035.
The Big Picture
The report highlights how the General Data Protection Regulation functions as a structural barrier to international medical research. This finding illustrates the tension between robust data privacy protections and the clinical agility required for global oncology trial competitiveness.
The reduction in local clinical trials may limit the availability of experimental or life-saving therapies for patients with rare and advanced cancer diagnoses. Patients may increasingly find themselves without access to the latest medical interventions within their own regions.
The takeaway
Advocacy groups are currently calling for urgent regulatory reform and increased funding to streamline research processes. Aligning national interpretations of clinical standards remains a critical step in preserving future access to experimental cancer treatments.
Further reading
For additional context on research and treatment trends, visit the Cancer section.
Source note: This article includes information reported by Euractiv DE.
Live Poll
Should the European Union dedicate more of its competitiveness funding to cancer research?
